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Bipolar Disorder (BD) is the 4th leading cause of disability worldwide among young people 
ages 10-24 years. Although the diagnosis is largely defined by the mood episodes 
associated with the illness, cognitive deficits are among the most persistent and disabling 
symptoms of illness and have a profound impact on clinical course and functional outcome. 
Specifically, trait-like impairment is common in the domains of attention, verbal learning, and 
executive function; these deficits contribute to functional disability and are targets for emerging 
treatments and preventions. Although considerable progress has been made over the past 
two decades, our understanding of the underlying causes of the cognitive deficits in BD 
remains surprisingly limited. As such, there are no approved treatments for this disabling 
symptom specific to BD1. 
 
Clinicians who treat patients with BD can attest to the vast range of functioning seen within 
BD, with some individuals achieving high-level occupational and social status while others are 
broadly disabled for most of their lives2. Research has shown that at the group level, cognitive 
deficits are present in euthymic BD patients, and are qualitatively similar to those seen in 
schizophrenia (SZ), albeit consistently less severe; however, group-level comparisons 
inherently fail to take into account heterogeneity in cognitive profiles within the disorder.  In 
stark contrast to the very high rates of cognitive deficits in SZ, data suggest that approximately 
30-50% of BD patients present as “neuropsychologically normal” (not different from age-
matched non-psychiatric controls) during periods of euthymia3. We cannot yet answer the 
critical question of why some patients with BD develop significant cognitive deficits while 
others appear relatively resilient to cognitive decline and maintain high levels of social and 
occupational functioning. Large-scale studies are needed to better identify both risk and 
resilience factors for cognitive impairment in BD. 
 
What diagnostic and clinical factors account for cognitive and functional heterogeneity in BD? 
Several clinical factors have been associated with cognitive impairment in BD, including 
bipolar subtype (BD I versus BD II); however, considerable discrepancy is notable across 
studies, and recent meta-analyses suggest that between-group differences are very subtle4. 
Previously-reported subgroup differences may be - at least in part - due to the greater 
frequency of psychosis in BD I vs BD II, but individual studies have thus far been 
underpowered to test these types of fine-grained hypotheses. Beyond diagnostic 
heterogeneity, the course of the illness varies considerably among BD patients and is 
thought to contribute to cognitive and functional outcomes. Meta-analytic (cross-sectional) 
data suggest that a longer duration of illness, higher number of prior mood episodes, and 
history of psychosis are associated with more pronounced cognitive impairment indicative of 
a neuroprogressive course; however, each individual study has been small and thereby 
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unable to address specific questions such as whether the polarity of prior episodes, duration 
of illness, or medication effects are relevant to cognitive outcome. Interestingly, very few 
studies have adequately addressed one of the most basic questions in BD – how does current 
symptom severity affect the nature and extent of cognitive impairment and is this a 
bidirectional effect? Many other illness-related factors are likely to contribute to cognitive and 
functional outcomes in BD (e.g. sleep, obesity, comorbid medical and psychiatric conditions, 
among others); however, these are relatively understudied and sample sizes are modest. 
 
In an effort to advance the field through collaboration and open data-sharing, we have 
initiated the first international consortium focused on this highly significant topic: The 
International Consortium Investigating Cognition in Bipolar Disorder (ICONIC-BD). This effort 
brings together a large, international team of experts in BD with existing data on cognition in 
individuals with BD to form a unique consortium with the ability to unambiguously address 
some of these important questions through large-scale mega-analyses.  
 
The idea for this project stemmed from the International Society for Bipolar Disorder (ISBD) 
Targeting Cognition Task Force meeting held in Mexico City in March 2018. All task force 
members were initially invited to contribute data to the consortium. Each investigator who 
had data to contribute enthusiastically agreed to do so – indicating a strong collaborative 
network. 
 
We have assembled a strong team of investigators from across the world to form ICONIC-
BD; however, to optimize the impact that this consortium will have, global outreach is 
necessary. We hope to identify other investigators via PubMed searches and word of mouth 
who have existing cognitive data in BD patients and invite them to join us. This will be open 
to any investigator with data to contribute who is interested in participating.  
 
The coordinating site for ICONIC-BD is the Brigham and Women’s Hospital (BWH); Harvard 
Medical School in Boston, Massachusetts – USA, led by Katherine Burdick. She is joined by 
co-leaders Kamilla Miskowiak (University of Copenhagen); Eduard Vieta (University of 
Barcelona); and Lakshmi Yatham (University of British Columbia) forming a 4-member 
executive committee who will oversee the effort. To date, we have already enlisted 
participation from a total of 15 sites who have provided meta-data for inclusion in this 
initiative (Table 1). Estimated sample sizes (as of 12/2018) are >3000 BD individuals and 
>2000 healthy controls. 
 
After evaluating the nature of the existing data, we have begun the development of a single 
platform (e.g. define variables of interest from each measure, provide uniform labels) into 
which each site will place their data for transfer to BWH and upon which the master 
database will be built. As different neurocognitive batteries were used across sites, data 
harmonization will be critical to optimize the utility of the merged dataset. Quality control 
methods will be implemented to handle missing values to optimize available information 
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while maintaining data integrity; data will be examined for normality and transformed as 
necessary; and all test scores will be converted to standard scales based upon the healthy 
control normative sample (e.g. z-scores with mean of zero and standard deviation of one).  
 
Preliminary analyses will be conducted to define primary outcome measures at three levels. 
Global outcomes will be calculated using principal components analyses (PCA) to derive a 
general cognitive ability ‘g’ score. This will be done in a standard manner where g is defined 
as the first factor from an unrotated PCA, which will be conducted separately as each site 
using the maximum number of tests available (but at least 3 tests) to calculate g. The global 
measure g has distinct advantages in consortium analyses, as it allows all cases (with at 
least 3 cognitive measures) to be included in analyses, regardless of the different batteries 
used at each site. This is based on data that show that when large samples have been 
tested on different cognitive test batteries, the derived general cognitive factors (g) correlate 
very highly with one another (approaching r =1.0); that is, g factors derived from different 
groups of tests rank people almost identically5. An additional advantage of this measure is 
that it captures a large percentage of the variance on other cognitive domains/tests and, as 
such, it is predictive of many important functional outcomes. The relative disadvantage is 
that g may not capture some of the more nuanced aspects of neurocognitive functioning that 
are impaired in BD or the cognitive heterogeneity that exists. As such, the second level of 
analyses will focus on domain-level outcomes, which will be defined based upon results from 
the PCA as well as calculating mean z-scores across similar pre-determined tasks. Finally, 
test-level outcomes will be selected based upon the most representative (and available) 
variables for each individual task. 
 
Data from other measures that are related to cognitive outcome in BD will also need to be 
summarized and merged into the database. This will include demographic information and 
several illness-related scales. Data from standardized mood ratings are available from each 
site; however, not all sites use the same scales [e.g. Montgomery Asberg (MADRS) vs 
Hamilton (HamD) depression rating scales]. As such, severity of mood symptoms at the time 
of assessment will be converted to a common metric to be used in analyses. Illness history 
captured by different diagnostic interviews (i.e. MINI vs SCID) will also be standardized to 
capture important diagnostic features (e.g. BD subtype; psychosis subtype; # prior episodes; 
comorbidities) on the same scale. Measures of everyday functioning, including interpersonal, 
occupational and independent living status will be incorporated to provide a benchmark of 
how cognitive capacity translates to some of the most important aspects of a patient’s life. 
Again, as different groups use unique tests to assess these constructs, we will devise 
metrics to allow for inclusion of data from multiple different scales. 
 
Data analyses will begin by asking the simple questions first, including but not limited to: a) 
As a group, how do BD patients compare with healthy controls on cognitive outcomes (case 
vs control)? b) How does current mood symptom severity influence cognition in BD? c) Do 
BD I patients differ from BD II patients on cognitive measures? d) Do BD patients with a 
history of psychosis fare worse than those without such a history? e) How does duration of 
illness influence cognitive performance, and is this relative to episode load? f) What role do 
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comorbidities (substance use disorders, anxiety disorders) play in cognitive outcome? g) 
How can we best address the confounder of medication effects on cognitive performance? 
The list of possible questions to be addressed is extensive and ICONIC-BD will provide a 
rich data set with unmatched statistical power to begin to answer many of them. 
 
While clinical outcome measures related to social, personal, and vocational functioning form 
the core of the collaboration, it is imperative to consider the course of cognitive capacity as 
the individual with BD ages. Since cognitive decline with age is an inevitable component of 
humanity, are individuals with BD affected sooner? How can the consequences of such 
decline be mitigated in the bipolar population? To study and answer such questions it is 
necessary to study a large population over time, in many cultures and locations.  
 
While these questions may seem straightforward, they have not yet been unambiguously 
answered in any single dataset. Moreover, with the power of collaboration, we will be able to 
conduct more sophisticated analyses to answer questions that can better address the multi-
factorial nature of cognition in BD. Analyses of mediators and moderators of cognitive 
outcome can address interactions among these key illness features. Classification methods 
(e.g. clustering, latent profiles) can be used to empirically parse cognitive heterogeneity, 
establishing potentially meaningful new ‘subtypes’ in the largest study to date. Addressing 
these complex questions is key to understanding what causes cognitive impairment in a 
large subset of patients with BD. This is the first (and a critical) step in determining how best 
to treat and ultimately prevent this disabling symptom, which would have direct and 
immediate effects on quality of life for many patients with BD. 
 
Beyond the initial set-up of this data base, ICONIC-BD will also serve as a platform for 
additional collaborative projects (e.g. subcommittees for those sites that have DNA, or those 
with neuroimaging data, or those interested in establishing a network for treatment trials 
targeting cognition). We hope that this dataset and interconnected worldwide network will 
also lead to additional funding for this very important and understudied area of research.  
 
The overarching goal of this initiative is the creation of the world’s largest, publicly-available 
database on cognition in BD. This will promote work that could not be done by any single 
investigator/lab. The massive success of other similar consortia in psychiatry [Psychiatric 
Genomics Consortium (PGC); Enhancing NeuroImaging Genetics through Meta-analysis 
(ENIGMA); Cognitive Genomics Consortium (COGENT), among others] provides strong 
support for scientific advances through the kind of collaboration and data sharing that is 
planned in ICONIC-BD. Moreover, collaborative initiatives such as ICONIC-BD may foster 
agreement across research groups, not only in analyzing the available data, but in 
generating new data using common instruments and methodologies moving forward. 
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TABLE 1. INITIAL SITES FOR ICONIC-BD 
Site Investigator name(s) Location
Brigham and Women’s Hospital/Harvard Katherine Burdick USA 
Copenhagen University Hospital Kamilla Miskowiak, Lars Kessing Denmark 
University of Otago Richard Porter New Zealand 
University of Melbourne  Tamsyn Van Rheenen Australia 
King’s College London Allan Young UK 
National Center for Neurology and Psychiatry Tomiki Sumiyoshi Japan 
University of Barcelona Eduard Vieta, Anabel Martinez-Aran Spain 
University of British Columbia Yatham Lakshmi, Ivan Torres Canada 
University of Sao Paulo Beny Lafer Brazil 
Newcastle University Peter Gallagher UK 
McLean Hospital Kathryn Eve Lewandowski USA 
University of Michigan Melvin McInnis USA 
Queens University Christopher Bowie, Philip Harvey, 
Ann Pulver 
Canada 
Vanderbilt University Neil Woodward, Stephan Heckers USA 
University of California at San Diego Lisa Eyler USA 
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